Skip to main content
. Author manuscript; available in PMC: 2017 Aug 6.
Published in final edited form as: PET Clin. 2017 Jul;12(3):269–288. doi: 10.1016/j.cpet.2017.02.001

Table 2.

Drugs approved for anti-HER2 therapy in HER2-positive breast cancer

Drug (Chemical Name) Classification Mechanism of Action Company FDA Approved
Trastuzumab Antibody Binds to extracellular segment of the HER2/neu receptor Genentech 1998
Pertuzumab Antibody Inhibits the dimerization of HER2 with other HER receptors Genentech 2012
Ado-trastuzumab emtansine Antibody–drug conjugate Binds at plus ends of cellular microtubules and inhibits cell division in tumor cells Genentech 2013
Lapatinib Tyrosine kinase inhibitor Interrupts HER2/neu and EGFR pathway GlaxoSmithKline 2007

Abbreviations: EGFR, epidermal growth factor receptor; FDA, Food and Drug Administration; HER2, human epidermal growth factor 2.